Share price performance of major big pharma C19 injection players over the last 5 years - Pfizer, Moderna, AstraZeneca and BioNTech

News ten days ago that only 4 million shots have been administered in the US and just 134,000 doses have been administered out of 4,085,000 doses shipped in Europe over the last month indicates that the word is out. The injections are useless, poorly made and toxic.

Here’s how markets are viewing the increasingly bad news for the main participants vying to kill and maim as many people as are still not embracing the maxim “WE DON’T WANT YOUR STEENKING VACCINES”.

The companies covered are Pfizer, Moderna, AstraZeneca and BioNTech.

First the current market values of each company (less than zero if the liability shields were not present). In US dollars billion.

Pfizer 181.3, Moderna, 37.5, AstraZeneca 208.5 (@$1.21/£), BioNTech 24.8

AstraZeneca is bigger than Pfizer!

Here’s the five year performance charts starting with Pfizer:

Three years of zero and down from a high of almost 60 bucks in December 2021 (-48%).

Now Moderna:

Zero return since November 2020 and down from a high of 450 bucks in September 2021 (-78%.)

BioNTech:

Zero return since November 2020 and down from a high of 389 bucks in August 2021 (-73%)

Now, what about the UK company that had the worst ratio of adverse events and deaths for its viral vector injection that was withdrawn after just a few months from the EU, though continued in India (under license to the Serum Institute) in Russia (via the clone Sputnik) and other corrupt and incompetent countries such as Canada and Australia.

AstraZeneca

There you go. Diversity (of earnings streams) is strength – AZN must have not relied so much on C19 injection profits in its portfolio of products compared to Pfizer, Moderna and BioNTech. It also must have a similar liability shield in all countries in which it participated – even if it did not have a mRNA injection!

For those who follow such things, historic Price/Earnings ratios are as below:

Pfizer – 8.8, Moderna – 37.3, BioNTech – 2.7 and AstraZeneca 35.6

The Price/Earnings indication is backward looking and indicates how many years it would take a company to earn its current share price. The market is forward looking and values companies on future earnings expectations per share. Lots of other estimates for various components of the operations of a company are needed to forecast earnings.

Of course, if no liability shield existed for these companies they would have negative values and would be in bankruptcy, So here you see the corruption of socialising liabilities and rewarding profits. A lot like the Paulson/Bernanke solution to the banking crisis, student loans and housing and pretty much any socialist policy that is not properly separated from anything to do with politics.

Onwards!

Please buy a subscription or donate a coffee (I drink a lot of coffee) - “God Bless You!” if you can’t or don’t want to contribute. Coffee donations here: https://ko-fi.com/peterhalligan - an annual subscription of 100 bucks is one third less than a $3 coffee a week!